Transmission of HIV from mothers to their infants can often be reduced through effective prevention programs. Unfortunately, some infants do become infected with HIV. Early diagnosis of their HIV-1 status allows children to receive appropriate medical care as quickly as possible. Roche’s dual-target HIV-1 Qualitative assay provides reliable and accurate information on whether the baby is truly infected with HIV or not.
Answering needs with innovative solutions
Infants born to mothers infected with HIV-1 may have maternal antibodies to HIV-1. Antibody tests are ineffective in children because of the mother’s antibodies remain in the child’s system following birth. In fact, antibody tests in infants may yield false positive results for up to 15 months, and the uncertainty surrounding the HIV status of the child has a negative effect on the potential clinical management of the child.1
The use of dried blood spots (DBS) can facilitate PCR testing, and make sample collection easy, even from the smallest infant. By spotting small quantities of blood and collecting it on specially designed collection cards, blood collection and sample transportation is simplified while minimizing stress for the mother and child.
The number of children younger than 15 receiving anti-retroviral therapy (ART) in low- and midle-income countries from 566.000 in 2011 to 630.000 in 2012.1
Expanding Prevent Mother-to-Child Transmission (PMTCT) Programs, and the use of more effective anti-retroviral regimens, have prevented 800.000 children from becoming newly infected between 2005 and end of 2012.5
65% of pregnant women living with HIV received ART medication in 2012 compared to 49% in 2009.2
HIV-exposed infants should be tested using specialized virological test. Yet, in 2013, only 42% of infants born to mothers livi9ng with HIV in low- and middle-income countries recieved this test within two months as recommended by WHO.3
Mother-to-child transmission rates declined 26% in 2009 to 17% in 2012.4
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Qualitative Test, v2.0 is a qualitative nucleic acid amplification test for the detection of HIV-1 RNA and proviral DNA in plasma, anticoagulated fresh whole blood and dried blood spots.
Detect simply and confidently for timely treatment
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Qualitative Test, version 2.0 is an in vitro diagnostic, total nucleic acid amplification test for the qualitative detection of Human Immunodeficiency Virus Type 1 (HIV-1) DNA and RNA (or total nucleic acid, TNA) in human plasma or dried blood spots using the COBAS® AmpliPrep Instrument for automated specimen processing and the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer for automated amplification and detection.
The test is a diagnostic test, indicated for individuals who are suspected to be actively infected with HIV-1. Detection of HIV-1 TNA is indicative of active HIV infection. Infants born to mothers infected with HIV-1 may have maternal antibodies to HIV-1, and the presence of HIV-1 nucleic acid in the infant indicates active HIV-1 infection. In adults, the test may be used as an aid in the diagnosis of HIV-1 infection.
Early HIV diagnosis that gives infants and young children a chance to receive timely medical care is a major challenge. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Qualitative Test, v2.0 assay provides reliable, accurate information on whether or not an infant is infected.
CE-IVD, not available in the United States
Access package inserts through your country’s Roche Diagnostics Website.
